What happened
Samsung Pharmaceutical reported separate results for FY2025: revenue of US$31.5M (+4.02% year on year), an operating loss of US$12.4M and net income of US$8.3M (from a loss a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$31.5M |
|---|---|
| Revenue vs a year earlier | +4.02% |
| Operating profit | −US$12.4M |
| Net income | US$8.3M |
| Period | FY2025 (separate) |
| Filed | 2026-02-09, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260209801202 → open original filing |
Source: DART. Information only, not investment advice.